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Abstract
Background: Set-shifting is impaired in people with anorexia nervosa (AN), but the underlying physiological and 
biochemical processes are unclear. Animal studies have established that glutamatergic pathways in the prefrontal 
cortex play an important role in set-shifting ability. However, it is not yet understood whether levels of serum 
glutamatergic amino acids are associated with set-shifting performance in humans. The aim of this study was to 
determine whether serum concentrations of amino acids related to glutamatergic neurotransmission (glutamine, 
glutamate, glycine, L-serine, D-serine) are associated with set-shifting ability in people with acute AN and those after 
recovery.
Methods: Serum concentrations of glutamatergic amino acids were measured in 27 women with current AN (AN 
group), 18 women recovered from AN (ANRec group) and 28 age-matched healthy controls (HC group). Set-shifting 
was measured using the Wisconsin Card Sorting Test (WCST) and the Trail Making Task (TMT). Dimensional measures of 
psychopathology were used, including the Eating Disorder Examination Questionnaire (EDEQ), the Maudsley 
Obsessive-Compulsive Inventory (MOCI) and the Hospital Anxiety and Depression Scale (HADS).
Results: Serum glutamine concentrations in the AN group (1,310.2 ± 265.6 μM, mean ± SD) were significantly higher 
(by approximately 20%) than those in the HC group (1,102.9 ± 152.7 μM, mean ± SD) (F(2, 70) = 6.3, P = 0.003, 95% CI 61.2 
to 353.4). Concentrations of serum glutamine were positively associated with markers of the illness severity: a negative 
correlation was present between serum glutamine concentrations and body mass index (BMI) and lowest BMI and a 
positive correlation was found between duration of illness and EDEQ. The AN group showed significantly impaired set 
shifting in the WCST, both total errors, and perseverative errors. In the AN group, there were no correlations between 
serum glutamine concentrations and set shifting.
Conclusions: Serum concentrations of glutamine may be a biomarker of illness severity in people with AN. It does not 
appear to be directly associated with changes in executive function.
Background
Specific cognitive characteristics have been observed in
people with eating disorders (ED) [1,2]. For example, set-
shifting difficulties have been found in people currently ill
with anorexia nervosa (AN), in an attenuated form in
people recovered from AN (ANRec) [3,4] and in unaf-
fected sisters [5]. The problem has also been identified in
bulimia nervosa (BN), schizophrenia [6], bipolar disorder
[7] and obsessive-compulsive disorder [8]. It appears to
be a trait as it is present in first-degree relatives of people
with schizophrenia [9] and bipolar disorder [10].
Glutamate is the principal excitatory neurotransmitter
in brain and is involved in cognitive functions such as
memory and learning [11]. As glutamate concentrations
in blood are correlated with those in cerebrospinal fluid
(CSF) [12,13], serum levels may influence glutamatergic
concentrations and functions in brain. This is of interest
because muscle breakdown and gluconeogenesis during
starvation is likely to increase serum glutamine. This pro-
posal has some indirect support from proton magnetic
resonance spectroscopy (MRS) studies, which have
reported that people with AN have lower levels of a com-
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bined measure of glutamate and glutamine (Glx) and of
N-acetyl aspartate (NAA) in the frontal grey matter [14].
Furthermore, executive functioning assessed using the
Wisconsin Card Sorting Test (WCST) has been shown to
be  a s s oc i a t ed  w i t h  G lx  l ev e l s  i n  t h e  a n t e r i o r  c i n g u l a t e
gyrus (ACC) [15]. It has also been proposed that the age-
related decline in set-shifting ability is associated with
alterations in glutamate receptor binding in the cingulate
cortex and dorsomedial striatum [16]. These various
studies suggest that the functioning of the glutamatergic
system in the prefrontal region may be related to the
impaired cognitive performance seen in people with AN
and in other psychiatric disorders [17,18]. Animal studies
support the idea that set shifting is associated with gluta-
matergic neurotransmission (for example, with N-
methyl-D-aspartate (NMDA) receptor function) [16,19-
21]. MRS studies of people with AN [14,15,22,23] have
shown heterogenous findings possibly due to method-
ological factors.
Based on the above findings, we hypothesised that,
firstly, alterations in serum concentrations of glutamater-
gic amino acids (glutamate, glutamine, glycine, L-serine
and D-serine) would be observed in individuals with AN
and those with recovered AN and, secondly, that such
alterations would be related to deficits in set-shifting abil-
ity in individuals with acute AN and those with recovered
AN.
Methods
Participants
Of the 73 women who participated in this study, 27 had
current AN (AN group), 18 had recovered from AN
(ANRec group) and 28 were healthy age-matched con-
trols (HC group) (Table 1). Individuals in the AN and
ANRec groups were recruited from the South London
and Maudsley National Health Service (NHS) Foundation
Trust volunteer register of individuals with past or cur-
rent ED. The HC group was recruited from volunteers in
the local community.
All participants in the AN group met the American
Psychological Society (APA) Diagnostic and Statistical
M a n u a l  o f  M e n t a l  D i s o r d e r s ,  f o u r t h  e d i t i o n  (DSM-IV)
criteria [24] for AN (20 with the restrictive subtype, 7
with the binge-purge subtype). Seven patients were diag-
nosed with major depressive disorders; one also had an
anxiety disorder and two had concurrent obsessive com-
pulsive disorders. The ANRec group was defined accord-
ing to the following criteria: (1) a history of AN of the
restrictive subtype as defined by DSM-IV, (2) mainte-
nance of a stable body mass index (BMI) between 18.5
and 24 kg/m2 for a minimum of 1 year, (3) regular men-
strual cycles (at least 10 cycles) during the past year, (4)
binge eating and purging behaviours absent for 1 year,
and (5) not having been prescribed any psychotropic
medication during the past year. Inclusion criteria for the
HC group were: (1) BMI between 19 and 26 kg/m2, (2) no
personal or family history of any psychiatric illness or ED,
and (3) no current use of psychotropic medication.
Groups were matched for age, ethnicity and educational
level.
Exclusion criteria for all participants included a history
of brain injury, psychosis, neurological or other severe
medical illness, alcoholism or drug abuse/dependence.
All participants had English as their first language. Ethical
approval for the study was obtained from the Institute of
Psychiatry and the South London and Maudsley NHS
Trust Research Ethics Committee. All participants pro-
vided written informed consent for participation in the
study.
Clinical and self-report measures of psychopathology
Current and lowest previous BMI was recorded for
patients in the AN and ANRec groups. Neuropsychologi-
cal assessments were carried out in all but three AN
patients. Dimensional measures of psychopathology were
used, including the Eating Disorder Examination Ques-
tionnaire (EDEQ) [25], which has four subscales of
Restraint (EDEQ-R), Eating Concern (EDEQ-E), Weight
Concern (EDEQ-W) and Shape Concern (EDEQ-S). The
Maudsley Obsessive Compulsive Inventory (MOCI) [26]
and the Hospital Anxiety and Depression Scale (HADS)
[27] were used as dimensional measures to assess current
anxiety, depression and obsessive-compulsive symptoms.
Assay of serum glutamatergic amino acids
Blood samples were drawn from all subjects by
venepuncture in the morning (9:00 to 12:00). Approxi-
mately 10 ml of peripheral venous blood was collected
into additive-free containers and the samples were stored
at -80°C until needed.
Measurement of amino acids was carried out using
methods described previously [18,28,29]. Serum levels of
glutamate, glutamine, and glycine were measured using
h i g h  pe rf o rm a n c e  l i q u i d  c h r o m a t o gr a p h y  ( H P L C)  [ 2 8] .
D-Serine and L-serine levels were determined by a col-
umn switching HPLC system with fluorescence detection
[30]. A total of 20 μl of the human serum was homoge-
nised in 180 μl of HPLC-grade methanol. Homogenates
were then centrifuged at 4,500 g for 10 min. Then, 20 μl of
supernatant was evaporated to dryness at 40°C and the
residue was rehydrated by adding 20 μl of H2O (HPLC
grade), 20 μl of 0.1 M borate buffer (pH 8.0) and 60 μl of
50 mM 4-fluoro-7-nitro-2,1,3-benzoxadiazole (NBD-F;
Tokyo Kasei Kogyo, Tokyo, Japan) in CH3CN (HPLC
grade). The reaction mixture was then heated at 60°C for
1 min, and immediately supplemented with 100 μl ofNakazato et al. Annals of General Psychiatry 2010, 9:29
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H2O/CH3CN (90/10) containing 0.1% trifluoroacetic acid
(TFA) to stop the reaction. A total of 10 μl of the resultant
solution was injected into the HPLC system [28,29].
Assessment of set-shifting ability
The WCST [31] and the Trail Marking Task (TMT) [32]
were used to assess executive function by the measure-
ment of set-shifting ability.
The WCST involves matching stimulus cards with one
of four category cards. The sorting rule (colour, shape or
number) changes unpredictably after 10 correct sorts.
The set-shifting outcome employed is the number of raw
perseverative errors.
The TMT is a traditional set-shifting task. It requires
participants to connect an alphabetical sequence on a
page in a 'dot-to-dot' fashion (trail A), before alternatively
linking numbers and letters in order (that is, 1-A-2-B-3-C
(trail B)). A computerised version of the TMT was
employed here [33]. The set-shifting outcome used was a
balanced variable of trail B minus trail A, to control for
baseline motor speed.
Statistical analysis
All data were analysed using SPSS V.17.0 for Windows
(SPSS, Chicago, IL, USA). Results are presented as mean
values ± standard deviation (SD). Two-way analysis of
variance (ANOVA) was carried out to test for the interac-
tion between the groups of participants, cognitive
impairment of set-shifting abilities and serological find-
ings. One-way ANOVA was used to test for differences in
clinical characteristics, neuropsychological tasks and
serum amino acids concentrations between the groups.
Where a significant overall difference between the groups
was observed in ANOVA, pairwise comparisons were
carried out using the Bonferroni-Dunn post hoc test to
test the significance of different combinations of groups
with respect to the outcome variables. Pearson's bivariate
correlation coefficients were calculated to examine the
Table 1: Clinical characteristics and findings of serum amino acids (one-way ANOVA)
AN (n = 27) ANRec (n = 18) HC (n = 28) F df P value
Age, years 27.7 ± 10.6 32.2 ± 11.1 26.9 ± 5.8 2.0 2, 70 0.14
Education, years 16.9 ± 3.2 17.0 ± 2.8 18.1 ± 2.1 1.5 2, 66 0.23
Duration, years 10.0 ± 10.6 6.6 ± 6.2 NA 13.7 2, 69 0.00
Age of onset, years 17.0 ± 4.4 18.4 ± 6.4 NA 152.7 2, 69 0.00
Current BMI, kg/m2 15.4 ± 1.6a**b** 19.8 ± 1.1b**c** 22.3 ± 2.5 85.6 2, 68 0.00
Lowest BMI, kg/m2 13.1 ± 1.6a** 14.2 ± 2.0c** 21.0 ± 2.4 111.2 2, 65 0.00
EDEQ R 4.3 ± 3.7a**b** 0.8 ± 0.9b** 0.6 ± 1.0 20.0 2, 68 0.00
EDEQ E 3.3 ± 1.5a**b** 0.4 ± 0.4b** 0.2 ± 0.2 86.9 2, 68 0.00
EDEQ W 4.1 ± 1.7a**b** 1.0 ± 0.9b** 0.5 ± 0.6 69.8 2, 68 0.00
EDEQ S 4.6 ± 1.6a**b** 1.5 ± 0.9b** 0.9 ± 0.7 80.2 2, 68 0.00
EDEQ G 3.9 ± 1.7a**b** 1.0 ± 0.8b** 0.5 ± 0.5 65.7 2, 67 0.00
MOCI 10.1 ± 6.0a** 8.7 ± 4.2c** 3.7 ± 2.8 14.6 2, 68 0.00
HADS anxiety 14.0 ± 4.4a**b** 8.7 ± 2.8b**c** 4.4 ± 3.3 45.9 2, 66 0.00
HADS depression 9.3 ± 5.5a**b** 3.4 ± 2.4b** 1.5 ± 2.6 28.7 2, 66 0.00
Serum Glu, μM 64.7 ± 32.3 45.0 ± 29.6 54.7 ± 23.1 2.7 2, 70 0.08
Serum Gln, μM 1,310.2 ± 265.6a** 1,159.0 ± 236.3 1,102.9 ± 152.7 6.3 2, 70 0.00
Serum glycine, M 294.8 ± 78.2 280.9 ± 82.9 255.1 ± 58.3 2.1 2, 70 0.13
Ratio of Glu/Gln 0.064 ± 0.065 0.042 ± 0.034 0.052 ± 0.025 1.3 2, 70 0.28
Serum D-serine, μM 2.2 ± 0.8 2.2 ± 0.8 1.9 ± 0.5 1.6 2, 70 0.21
Serum L-serine, μM 135.6 ± 53.7 158.4 ± 72.7 117.7 ± 60.9 2.4 2, 70 0.10
Values shown are mean ± SD; *P < 0.05; **P < 0.01.
aComparisons between AN and HC; bcomparisons between AN and ANRec; ccomparisons between ANRec and HC.
AN = anorexia nervosa; ANOVA = analysis of variance; ANRec = recovered from anorexia nervosa; BMI = body mass index; df = degrees of freedom; 
EDEQ R = Eating Disorder Examination Questionnaire Restraint Subscale; EDEQ E = Eating Concern Subscale; EDEQ W = Weight Concern Subscale; 
EDEQ S = Shape Concern Subscale; EDEQ G = Global Scale; Glu = Glutamate; Gln = Glutamine; HADS = Hospital Anxiety and Depression Scale; HC 
= healthy controls; MOCI = Maudsley Obsessive-Compulsive Inventory.Nakazato et al. Annals of General Psychiatry 2010, 9:29
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relationship between serum concentrations of the differ-
ent glutamatergic amino acids with clinical variables (age,
education, duration of illness, current BMI, lowest BMI),
and also with results from the neuropsychiatric dimen-
sional tests (EDEQ subscale, MOCI and HADS anxiety
and depression scores). The values of Cohen's d were cal-
culated to be 0.20, 0.50 and 0.80 (small, medium and large
effect size, respectively), and P values < 0.05 were consid-
ered statistically significant.
Results
Demographic and clinical characteristics
Table 1 shows the demographic and clinical characteris-
tics for all participants. There were no significant differ-
ences between the AN group and ANRec group in terms
of current age, years of education, age of illness onset,
duration of illness or lowest BMI. The ANRec group had
been recovered for a mean duration of 7.2 years (SD 6.4;
range 1 to 24). As expected, the AN group had a signifi-
cantly lower BMI and a significantly higher level of psy-
chopathology (as determined by the EDEQ and HADS
anxiety and depression scores) than the ANRec and the
HC groups. The effect sizes were calculated to be 1.16 for
EDEQ-R, 1.56 for HADS anxiety and 1.38 for HADS
depression scores. The ANRec group showed signifi-
cantly higher levels of anxiety on MOCI and HADS anxi-
ety testing compared with the HC group.
Serum concentrations of amino acids
Two-way ANOVA revealed no between-subjects effects
of group or set shifting on serum concentration of amino
acids.
Table 1 shows the concentrations of amino acids
between the three groups. Serum glutamine concentra-
tions in the AN group (n = 27) (1,310.2 ± 265.6 μM, mean
± SD) were significantly higher than those in the HC
group (n = 28) (1,102.9 ± 152.7 μM, mean ± SD) (F(2, 70) =
6.3; P = 0.003) (Figure 1). Table 2 shows the results of the
post hoc Bonferroni-Dunn test for serum glutamine con-
centrations. Serum glutamine concentrations were signif-
icantly higher in the AN group than in the HC group (P =
0.003; 95% CI 61.2 to 353.4). The effect size for the mean
differences in serum glutamine was 0.87, which is a large
effect. There were no significant differences in the serum
concentrations of the other amino acids (glutamate, gly-
cine,  D-serine and L-serine) between the three groups.
The effect sizes for these were of a small and medium
size: 0.36 for glutamate, 0.56 for glycine, 0.44 for D-serine
and 0.31 for L-serine, respectively.
Neuropsychological findings
Group comparisons for the neuropsychological tasks are
presented in Table 3. The AN group showed significantly
impaired set shifting on the WCST (both total errors and
perseverative errors). The effect sizes were 0.71 for the
total errors and 0.68 for perseverative errors. The scores
for the ANRec group were between those of the AN
group and the HC group, and this difference was not sta-
tistically significant.
Correlations between serum glutamine concentrations, 
cognitive function and psychopathological features of EDs
In the sample that included the AN group and the ANRec
group (n = 45), a negative correlation was found between
serum glutamine concentrations and BMI (P = 0.026; r = -
0.339), and lowest BMI (P = 0.01; r = -0.386). A positive
correlation was found between serum glutamine concen-
trations and HADS anxiety scores (P = 0.005; r = 0.433).
There were also positive correlations between serum glu-
tamate concentrations and EDEQ-W scores (P = 0.006; r
= 0.413) and EDEQ-S (P = 0.03; r = 0.332). In the AN
group (n = 27), there was a positive correlation between
serum glutamate and the scores on EDEQ-W (P = 0.048; r
= 0.399).
Regression analysis
To investigate the relative importance of measured vari-
ables as predictors of eating-related psychopathology,
multiple regression analyses of selected variables (serum
D-serine, serum L-serine, serum glycine, serum glu-
tamine, serum glutamate and glutamate/glutamine ratio)
were carried out on WCST, EDEQ, HADS anxiety and
HADS depression scores. Stepwise regression analysis
indicated that serum glutamate levels in the AN group
predicted EDEQ-W scores. In the total sample, stepwise
regression analyses also indicated that serum glutamine
levels predicted anxiety and depression. When glutamine
Table 2: Post hoc Bonferroni tests for the serum glutamine concentrations
Group 95% CI P value
AN (n = 27) HC (n = 28) 61.2 to 353.4 0.003*
ANRec (n = 18) -13.6 to 316 0.083
HC (n = 28) ANRec (n = 18) -219.7 to 107.5 1.000
One-way ANOVA, Post hoc Bonferroni test.
*P < 0.05.
AN = anorexia nervosa; ANOVA = analysis of variance; ANRec = recovered from anorexia nervosa; HC = healthy controls.Nakazato et al. Annals of General Psychiatry 2010, 9:29
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was eliminated from this regression model, 18.8% of the
variance that predicted anxiety scores was explained (R2 =
0.188, P = 0.012, 95% CI -13.1 to 2.7, β = 0.434) along with
21.4% of the variance that predicted depression scores (R2
= 0.214, β = 0.462, P = 0.007). In the AN group, one com-
ponent, serum glutamate was extracted and found to
explain 90.8% of the predictive variance of EDEQ-W
scores (R2 = 0.908, P = 0.047, 95% CI -2.14 to 4.431, β =
0.953). No other variables were found to predict ED clini-
cal components or set-shifting performance.
Figure 1 Comparison of serum glutamine concentrations and serum glutamate concentrations in the healthy controls (HC), the patients 
with anorexia nervosa (AN) and those recovered from AN (ANRec). Values are mean ± SD; **P < 0.01.
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Discussion
In this study, we found that serum glutamine concentra-
tions in women currently ill with AN were significantly
higher than in a healthy control group of women. The
effect size for the mean differences in serum glutamine
was 0.87, which is a large effect size. The effect sizes were
0.36 for serum glutamate, 0.56 for serum glycine, 0.44 for
D-serine, 0.31 for L-serine: these are between a small and
a medium size. Secondly, our data shows that elevated
concentrations of serum glutamine are associated with
illness severity. For example, serum glutamine concentra-
tions were negatively correlated with BMI and lowest
BMI, and there was a positive correlation between the
serum glutamine concentration and duration of illness,
and also the EDEQ score. As elevated serum glutamine
concentrations are likely to be derived from muscle
breakdown and gluconeogenesis during starvation, it is
suggested that increased serum glutamine is a state
marker for the physiological severity of the AN. Our sec-
ond hypothesis, namely that serum glutamine concentra-
tions would be related to impairment of set-shifting
abilities in people with AN was not confirmed.
Depression has a lifetime prevalence of 5% to 10% of
young women and has a high comorbidity with AN. Pre-
vious studies found that plasma levels of glutamine, glu-
tamate were significantly increased in female patients
with depression [33,34]. Given that depression may
reflect disturbances in glutamatergic activity, screening
HC controls on psychiatric history might bias the results
and that the screening for exclusion should have been
based on history of ED only.
In this study, there were no significant differences in the
levels of the glutamine/glutamate ratio between the AN
and the HC group (Table 1). The amino acid glutamine is
involved in glutamate uptake, and although this study was
not designed as a turnover study, we hypothesised that
we would be able to recognise an altered glutamatergic
cycle in patients with AN. The levels of serum glutamine
in the AN group were found to be higher than those in
the HC group. One possibility is that in severe AN, raised
serum glutamine is a compensatory metabolic response
for having decreased levels in the brain due to malnutri-
tion.
The main endogenous source of circulating glutamine
is de novo synthesis in striated muscle via the enzyme
glutamine synthetase (GS). In animal studies, GS plays a
key role in mounting the adaptive response to fasting by
transiently facilitating the production of glutamine [35].
Intracellular concentrations of amino acids in the skeletal
muscle of healthy non-obese people decrease markedly
during fasting; after 3 days of fasting the glutamine con-
centrations are seen to have fallen [36]. The previous
report showed that in AN, reduced body protein could be
confirmed by measurement of the triceps skinfold thick-
ness [37]. Taken together, elevated serum glutamine
appears to be derived from muscle breakdown and gluco-
neogenesis during starvation, which in turn is related to
BMI and duration of illness. Our second hypothesis that
serum glutamatergic amino acids would be related to
cognitive impairment of set-shifting abilities in people
with AN was not confirmed.
In this study, the AN group showed significantly
impaired set-shifting in the WCST, both total errors and
perseverative errors. The scores in the recovered group
were inbetween those of participants in the acute phase
of the illness and HC. Neuropsychological function using
WCST was worse in AN participants in comparison with
the control group, which was similar to the findings of
previous studies [1-5,38].
The limitations of this study were a small sample size
and a cross-sectional design. Thus we could not conclude
whether serum glutamatergic neurotransmission were
associated with set-shifting difficulties both in acute AN
and ANRec. A longitudinal study is required, using a
larger sample size and exploring other central coherence
tasks, in order to clarify whether glutamatergic amino
acids are a biological markers for certain endophenotypes
of AN.
Finally, it is unclear whether serum glutamatergic con-
centrations in humans accurately reflect levels in the
brain. Such concentrations might represent breakdown of
muscle in the periphery, as products of gluconeogenesis,
Table 3: Neuropsychological findings of set shifting (performance on the WCST and the Trail Making Task (TMT))
AN (n = 24) ANRec (n = 18) HC (n = 28)
Trail shifting time 33.3 ± 17.6 29.6 ± 11.3 29.1 ± 8.6
Trail shifting errors 2.0 ± 6.5 0.6 ± 1.0 0.4 ± 0.6
WCST total errors, % 24.0 ± 15.6a** 17.6 ± 8.5 14.9 ± 7.7
WCST perseverative errors, % 13.0 ± 10.4a** 8.7 ± 3.5 7.6 ± 3.4
Values are mean ± SD; *P < 0.05; **P < 0.001.
aComparisons between AN and HC; bcomparisons between AN and ANRec; ccomparisons between ANRec and HC.
AN = anorexia nervosa; ANRec = recovered from anorexia nervosa; HC = healthy controls; WCST = the Wisconsin Card Sorting Test.Nakazato et al. Annals of General Psychiatry 2010, 9:29
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rather than reflect changing levels in the brain. Further
studies are required to confirm what alterations in gluta-
matergic neurotransmission occur in the brain of individ-
uals with AN, and how it relates to the pathophysiology.
This could be performed using MRS to directly assess the
levels of glutamine in the frontal grey matter.
Conclusions
Elevated serum glutamine may be related to the
pathophysiology of AN but does not appear to be linked
to functional changes in executive function. Further lon-
gitudinal studies are required to explore the associations
between glutamatergic amino acid metabolism and cog-
nitive flexibility in AN.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MN wrote the protocol and carried out the recruitment of the participants, per-
formed the statistical analyses. KH participated in the design and carried out
assay of glutamatergic amino acids. US participated in the design, coordination
of the study. KT participated in coordination of the neuropsychological assess-
ment. ICC participated in the design, the interpretation of data, revised the
manuscript draft. DAC participated in the design, the management of blood
samples. MI participated in the design of the study. JT participated in its design
and coordination of the study. All authors participated in the interpretation of
data, revised it critically for important intellectual content and have read and
approved the final manuscript.
Acknowledgements
We thank our participants for giving their time to take part in this project.
Author Details
1Section of Eating Disorders, Institute of Psychiatry, King's College London, UK, 
2Department of Child Psychiatry, Chiba University Hospital, Chiba, Japan, 
3Division of Clinical Neuroscience, Chiba University Center for Forensic Mental 
Health, Chiba, Japan, 4Division of Psychological Medicine and Social Genetic 
and Developmental Psychiatry Centre, Institute of Psychiatry, King's College 
London, UK, 5Department of Psychiatry, Chiba University Graduate School of 
Medicine, Chiba, Japan and 6Division of Psychological Medicine, Eating 
Disorders Research Unit, Department of Academic Psychiatry, King's College, 
Guy's Hospital, London, UK
References
1. Roberts M, Tchanturia K, Stahl D, Southgate L, Treasure J: A systematic 
review and meta-analysis of set-shifting ability in eating disorders.  
Psychosom Med 2007, 37:1075-1084.
2. Lopez C, Tchanturia K, Stahl D, Treasure J: Weak central coherence in 
eating disorders: a step towards looking for an endophenotype of 
eating disorders.  J Clin Exp Neuropsychol 2009, 31:117-125.
3. Tchanturia K, Morris R, Anderluh B, Collier D, Nikolaou V, Treasure J: Set 
shifting in anorexia nervosa: an examination before and after weight 
gain, in full recovery and relationship to childhood and adult OCPD 
traits.  J Psychiatr Res 2004, 38:545-552.
4. Tchanturia K, Campbell I, Morris R, Treasure J: Neuropsychological studies 
in anorexia nervosa.  Int J Eat Disord 2005, 37(Suppl):72-76.
5. Holliday J, Tchanturia K, Landau S, Collier D, Treasure J: Is impaired set-
shifting an endophenotype of anorexia nervosa?  Am J Psychiatry 2005, 
162:2269-2275.
6. Wobrock T, Ecker UK, Scherk H, Schneider-Axmann T, Falkai P, Gruber O: 
Cognitive impairment of executive function as a core symptom of 
schizophrenia.  World J Biol Psychiatry 2009, 10:442-451.
7. Sachs G, Schaffer M, Winklbaur B: Cognitive deficits in bipolar disorder.  
Neuropsychiatr 2007, 21:93-101.
8. Rao NP, Reddy YC, Kumar KJ, Kandavel T, Chandrashekar CR: Are 
neuropsychological deficits trait markers in OCD?  Prog 
Neuropsychopharmacol Biol Psychiatry 2008, 32:1574-1579.
9. Snitz BE, Macdonald AW, Carter CS: Cognitive deficits in unaffected first-
degree relatives of schizophrenia patients: a meta-analytic review of 
putative endophenotypes.  Schizophr Bull 2006, 32:179-194.
10. Bora E, Yucel M, Pantelis C: Cognitive endophenotypes of bipolar 
disorder: a meta-analysis of neuropsychological deficits in euthymic 
patients and their first-degree relatives.  J Affect Disord 2009, 113:1-20.
11. Jamain S, Betancur C, Quach H, Philippe A, Fellous M, Giros B, Gillberg C, 
Leboyer M, Bourgeron T, Paris utism Research International Sibpair (PARIS) 
Study: Linkage and association of the glutamate receptor 6 gene with 
autism.  Mol Psychiatry 2002, 7:302-310.
12. McGale EH, Pye IF, Stonier C, Hutchinson EC, Aber GM: Studies of the 
inter-relationship between cerebrospinal fluid and plasma amino acid 
concentrations in normal individuals.  J Neurochem 1977, 29:291-297.
13. Alfredsson G, Wiesel FA, Tylec A: Relationships between glutamate and 
monoamine metabolites in cerebrospinal fluid and serum in healthy 
volunteers.  Biol Psychiatry 1988, 23:689-97.
14. Castro-Fornieles J, Bargalló N, Lázaro L, Andrés S, Falcon C, Plana MT, 
Junqué C: Adolescent anorexia nervosa: cross-sectional and follow-up 
frontal gray matter disturbances detected with proton magnetic 
resonance spectroscopy.  J Psychiatr Res 2007, 41:952-958.
15. Ohrmann P, Kersting A, Suslow T, Lalee-Mentzel J, Donges US, Fiebich M, 
Arolt V, Heindel W, Pfleiderer B: Proton magnetic resonance 
spectroscopy in anorexia nervosa: correlations with cognition.  
Neuroreport 2004, 15:549-553.
16. Nicolle MM, Baxter MG: Glutamate receptor binding in the frontal 
cortex and dorsal striatum of aged rats with impaired attentional set-
shifting.  Eur J Neurosci 2003, 18:3335-3342.
17. Goff D, Coyle J: The emerging role of glutamate in the pathophysiology 
and treatment of schizophrenia.  Am J Psychiatry 2001, 158:1367-1377.
18. Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda 
N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: 
Decreased serum levels of D-serine in patients with schizophrenia: 
evidence in support of the N-methyl-D-aspartate receptor 
hypofunction hypothesis of schizophrenia.  Arch Gen Psychiatry 2003, 
60:572-576.
19. Roberts AC, Robbins TW, Everitt BJ, Muir JL: A specific form of cognitive 
rigidity following excitotoxic lesions of the basal forebrain in 
marmosets.  Neuroscience 1992, 47:251-264.
20. Stefani MR, Groth K, Moghaddam B: Glutamate receptors in the rat 
medial prefrontal cortex regulate set-shifting ability.  Behav Neurosci 
2003, 117:728-737.
21. Darrah JM, Stefani MR, Moghaddam B: Interaction of N-methyl-D-
aspartate and group 5 metabotropic glutamate receptors on 
behavioral flexibility using a novel operant set-shift paradigm.  Behav 
Pharmacol 2008, 19:225-234.
22. Roser W, Bubl R, Buergin D, Seelig J, Radue EW, Rost B: Metabolic changes 
in the brain of patients with anorexia and bulimia nervosa as detected 
by proton magnetic resonance spectroscopy.  Int J Eat Disord 1999, 
26:119-136.
23. Schlemmer HP, Möckel R, Marcus A, Hentschel F, Göpel C, Becker G, Köpke 
J, Gückel F, Schmidt MH, Georgi M: Proton magnetic resonance 
spectroscopy in acute, juvenile anorexia nervosa.  Psychiatry Res 1998, 
82:171-179.
24. American Psychiatric Association: Diagnostic and Statistical Manual of 
Mental Disorders 4th edition. Washington DC: American Psychiatric Press; 
1994. 
25. Fairburn C, Beglin S: Assessment of eating disorders: interview or self-
report questionnaire?  Int J Eat Disord 1994, 16:363-370.
26. Hodgson R, Rachman S: Obsessional-compulsive complains.  Behav Res 
Ther 1977, 15:389-395.
27. Zigmond A, Snaith R: The hospital anxiety and depression scale.  Acta 
Psychiatr Scand 1983, 67:361-370.
28. Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindström L, Iyo M: 
Elevated glutamine/glutamate ratio in cerebrospinal fluid of first 
episode and drug naive schizophrenic patients.  BMC Psychiatry 2005, 
31:6.
Received: 24 February 2010 Accepted: 25 June 2010 
Published: 25 June 2010
This article is available from: http://www.annals-general-psychiatry.com/content/9/1/29 © 2010 Nakazato et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Annals of General Psychiatry 2010, 9:29Nakazato et al. Annals of General Psychiatry 2010, 9:29
http://www.annals-general-psychiatry.com/content/9/1/29
Page 8 of 8
29. Yamada K, Ohnishi T, Hashimoto K, Ohba H, Iwayama-Shigeno Y, 
Toyoshima M, Okuno A, Takao H, Toyota T, Minabe Y, Nakamura K, Shimizu 
E, Itokawa M, Mori N, Iyo M, Yoshikawa T: Identification of multiple serine 
racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO 
in schizophrenia and D-serine levels.  Biol Psychiatry 2005, 57:1493-1503.
30. Fukushima T, Kawai J, Imai K, Toyo'oka T: Simultaneous determination of 
D- and L-serine in rat brain microdialysis sample using a column-
switching HPLC with fluorimetric detection.  Biomed Chromatogr 2004, 
18:813-819.
31. Heaton RK, Chelune GJ, Talley JL, Kay G, Curtiss G: Wisconsin Card Sorting 
Test. Computer version 4th edition. Edited by: Odessa FL. Psychological 
Assessment Resources; 1993. 
32. Reitan RM: The relation of the trail making test to organic brain 
damage.  J Consult Psychol 1955, 19:393-394.
33. Küçükibrahimoğlu E, Saygin MZ, Calis ¸kan M, Kaplan OK, Unsal C, Gören 
MZ: The change in plasma GABA, glutamine and glutamate levels in 
fluoxetine- or S-citalopram-treated female patients with major 
depression.  Eur J Clin Pharmacol 2009, 65:571-577.
34. Mitani H, Shirayama Y, Yamada T, Maeda K, Ashby CR Jr, Kawahara R: 
Correlation between plasma levels of glutamate, alanine and serine 
with severity of depression.  Prog Neuropsychopharmacol Biol Psychiatry 
2006, 30:1155-1158.
35. Kravariti E, Morris RG, Rabe-Hesketh S, Murray RM, Frangou S: The 
Maudsley Early Onset Schizophrenia Study: cognitive function in 
adolescent-onset schizophrenia.  Schizophr Res 2003, 65:95-103.
36. He Y, Hakvoort TB, Koehler SE, Vermeulen JL, de Waart DR, de Theije C, Ten 
Have GA, van Eijk HM, Kunne C, Labruyere WT, Houten SM, Sokolovic M, 
Ruijter JM, Deutz NE, Lamers WH: Glutamine synthetase in muscle is 
required for glutamine production during fasting and extrahepatic 
ammonia detoxification.  J Biol Chem 2010, 285:9516-9524.
37. Kerruish KP, O'Connor J, Humphries IR, Kohn MR, Clarke SD, Briody JN, 
Thomson EJ, Wright KA, Gaskin KJ, Baur LA: Body composition in 
adolescents with anorexia nervosa.  Am J Clin Nutr 2002, 75:31-37.
38. Zastrow A, Kaiser S, Stippich C, Walther S, Herzog W, Tchanturia K, Belger 
A, Weisbrod M, Treasure J, Friederich HC: Neural correlates of impaired 
cognitive-behavioral flexibility in anorexia nervosa.  Am J Psychiatry 
2009, 166:608-616.
doi: 10.1186/1744-859X-9-29
Cite this article as: Nakazato et al., Serum glutamine, set-shifting ability and 
anorexia nervosa Annals of General Psychiatry 2010, 9:29